Subtype
Malignant Soft Tissue Neoplasm of Uncertain Differentiation
CI-CAN-00001179Explore in graph →
66 active trials2 approved drugs25 evidence items
- NCIt
- C6588
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001179Explore in graph →
Clinical trials
186 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (29)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07502716 | Compassionate Use of Ubamatamab | available | — | — | Regeneron PharmaceuticalsINDUSTRY | 0 | Mar 31, 2026 | clinicaltrials |
| NCT06789081 | GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient With Alveolar Soft Part Sarcoma (CLIC-YYC-GPNMB-02) | active not recruiting | Early Phase 1 | 1 | AHS Cancer Control AlbertaOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT04420975 | Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma | active not recruiting | Phase 1 | 14 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04008238 | Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients(PIPER) | completed | N/A | 29 | Institut BergoniéOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT03016819 | Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)(APROMISS) | recruiting | Phase 3 | 325 | Advenchen Laboratories, LLCINDUSTRY | 5 | Feb 25, 2026 | clinicaltrials |
| NCT07432932 | Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients(PANTHR-S) | recruiting | — | 800 | Royal Marsden NHS Foundation TrustOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06709495 | Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas | recruiting | Phase 1 / Phase 2 | 63 | David S Shulman, MDOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT03967834 | Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group(MIRAS) | recruiting | N/A | 400 | Institut Claudius RegaudOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT01391962 | Sunitinib or Cediranib for Alveolar Soft Part Sarcoma | completed | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | Feb 2, 2026 | clinicaltrials |
| NCT04390737 | Evaluate the Safety and Clinical Activity of HH2853 | recruiting | Phase 1 / Phase 2 | 254 | Haihe Biopharma Co., Ltd.INDUSTRY | 2 | Jan 30, 2026 | clinicaltrials |
| NCT07169344 | Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma(PROSARC-1) | recruiting | Phase 2 | 110 | Oslo University HospitalOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07173972 | Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.(PROSARC-2) | recruiting | Phase 2 | 40 | Oslo University HospitalOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT01231906 | Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma | completed | Phase 3 | 642 | Children's Oncology GroupNETWORK | 6 | Jan 23, 2026 | clinicaltrials |
| NCT04995003 | HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma | recruiting | Phase 1 | 25 | Baylor College of MedicineOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT04690374 | Registry to Collect Health Information About Desmoplastic Small Round Cell Tumor | recruiting | — | 250 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT06849986 | IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)(TAIS) | recruiting | Phase 2 | 45 | Fudan UniversityOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT06946225 | ACTengine® IMA203 Combined With mRNA-4203 | recruiting | Phase 1 | 15 | Immatics US, Inc.INDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT04204941 | Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma | terminated | Phase 1 | 25 | Epizyme, Inc.INDUSTRY | 4 | Jan 7, 2026 | clinicaltrials |
| NCT06942442 | A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma | recruiting | Phase 2 | 47 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT02869217 | Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors | active not recruiting | Phase 1 | 22 | University Health Network, TorontoOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT03618381 | EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | active not recruiting | Phase 1 | 44 | Seattle Children's HospitalOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT03099681 | An Observational Study on Epithelioid Sarcoma(EPISObs) | recruiting | — | 100 | Italian Sarcoma GroupNETWORK | 1 | Nov 18, 2025 | clinicaltrials |
| NCT02875548 | A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study(TRuST) | completed | Phase 1 / Phase 2 | 58 | Epizyme, Inc.INDUSTRY | 7 | Nov 4, 2025 | clinicaltrials |
| NCT02162732 | Molecular-Guided Therapy for Childhood Cancer | completed | N/A | 186 | Giselle ShollerOTHER | 2 | Nov 3, 2025 | clinicaltrials |
| NCT05296564 | Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers | recruiting | Phase 1 / Phase 2 | 3 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT07153887 | Vebreltinib for Advanced or Metastatic CCS | recruiting | Phase 2 | 30 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT06683846 | Ivonescimab in the Treatment of Multiple Advanced Tumors | recruiting | Phase 2 | 400 | Fudan UniversityOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT06277154 | MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma | recruiting | Phase 2 | 148 | HRYZ Biotech Co.INDUSTRY | 1 | Jul 24, 2025 | clinicaltrials |
| NCT06827886 | GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient With Alveolar Soft Part Sarcoma(GCAR1) | completed | Early Phase 1 | 1 | AHS Cancer Control AlbertaOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT07066982 | Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas(BAH2573-103) | recruiting | Phase 1 / Phase 2 | 60 | Essen BiotechOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT04530487 | Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults | terminated | Phase 2 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT02601950 | A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma | completed | Phase 2 | 267 | Epizyme, Inc.INDUSTRY | 9 | Jun 22, 2025 | clinicaltrials |
| NCT01125449 | Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease | withdrawn | Phase 2 | 0 | Situs Cancer Research CenterOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT06813417 | CAR T Therapy With GCAR1 for Relapsed Alveolar Soft Part Sarcoma(SPS-Q2) | active not recruiting | Early Phase 1 | 1 | University of CalgaryOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT04965753 | FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors | terminated | Phase 1 | 55 | Foghorn Therapeutics Inc.INDUSTRY | 4 | Mar 4, 2025 | clinicaltrials |
| NCT00942877 | Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma | completed | Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Mar 3, 2025 | clinicaltrials |
| NCT06836505 | Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial. | recruiting | Phase 1 / Phase 2 | 10 | Sun Yat-Sen University Cancer CenterOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT04095221 | A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma | completed | Phase 1 / Phase 2 | 21 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT04213794 | Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients(TOASTIT) | terminated | Early Phase 1 | 2 | Mayo ClinicOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT04537715 | Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels | completed | Phase 1 | 42 | Epizyme, Inc.INDUSTRY | 2 | Feb 19, 2025 | clinicaltrials |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT06456359 | Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor(PAMSARC) | recruiting | Phase 2 | 28 | University Hospital HeidelbergOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT06748872 | EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma(EPITOME-1015-I) | not yet recruiting | Phase 1 | 55 | Medigene AGINDUSTRY | 1 | Dec 27, 2024 | clinicaltrials |
| NCT04028479 | The Registry of Oncology Outcomes Associated With Testing and Treatment(ROOT) | completed | — | 167 | Taproot HealthINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT05355753 | A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors | terminated | Phase 1 | 49 | C4 Therapeutics, Inc.INDUSTRY | 1 | Dec 17, 2024 | clinicaltrials |
| NCT03250325 | Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients with Synovial Sarcoma | completed | Phase 1 / Phase 2 | 8 | Takara Bio Inc.INDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT02601937 | EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma | completed | Phase 1 | 109 | Epizyme, Inc.INDUSTRY | 9 | Oct 3, 2024 | clinicaltrials |
| NCT03604783 | Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors | terminated | Phase 1 | 74 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06526897 | Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma | not yet recruiting | N/A | 1,582 | ECOG-ACRIN Cancer Research GroupNETWORK | 0 | Jul 30, 2024 | clinicaltrials |
| NCT02636725 | Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas | completed | Phase 2 | 33 | Jonathan Trent, MD, PhDOTHER | 1 | Jul 12, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Mar 31, 2026source: clinicaltrials